Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00

By TheFly | March 11, 2026, 6:00 AM

The deal size was increased to $650M in common stock from $500M in common stock. JPMorgan, Jefferies, TD Cowen, Stifel, RBC Capital and William Blair acted as joint book running managers for the offering.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on XENE:

Disclaimer & Disclosure Report an Issue

Mentioned In This Article

XENE

-2.66%

Xenon Pharmaceuticals Inc

Latest News

Oct-02	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Oct-01	Xenons Insider Buying Tops $1.6M XENE Stock Heads For Best Day In Over Month XENE Stocktwits
Sep-29	Ian Mortimer Receives the 2026 Bloom Burton Award XENE TMX Newsfile
Sep-29	Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors XENE TMX Newsfile
Sep-21	Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit XENE GlobeNewswire
Sep-21	Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment XENE TIKR
Sep-18	This Biotech Surged 50% On Positive Data In March. Now, It's Completely Gone. XENE -30.69% Investor's Business Daily
Sep-18	Xenon Pharmaceuticals falls 30% after depression trial enrollment pause XENE -30.69% Proactive
Sep-18	Netflix downgraded, Etsy upgraded: Wall Street's top analyst calls XENE -30.69% The Fly
Sep-18	Premarket movers: Xenon sinks on trial pause, Netflix hit by downgrade XENE -30.69% Investing.com
Sep-18	Xenon Stock Faces Worst Day Since 2017 as Lead Drug Proves a Double-Edged Sword XENE -30.69% Barrons.com
Sep-18	Premarket movers: Intel, Coinbase, Nucor and Xenon XENE -30.69% MarketWatch
Sep-18	Stock Market Today: Dow set to slip, S&P 500 and Nasdaq head for steady open as oil prices dip but yields tick higher XENE -30.69% MarketWatch
Sep-17	Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program XENE GlobeNewswire
Sep-10	Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow. XENE Barrons.com

Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00

Claim 70% Off TipRanks Premium

Mentioned In This Article

Latest News

Upgrade your Finviz experience